Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Professor Paul Workman Joins Nuevolution as Scientific Advisor

Published: Friday, July 11, 2014
Last Updated: Thursday, July 10, 2014
Bookmark and Share
Professor Workman brings a vast knowledge and expertise within the oncology field.

Nuevolution has announced that Professor Paul Workman has joined as Scientific Advisor. Paul brings a vast knowledge and expertise within the oncology field to Nuevolution as well as profound understanding of bridging research discoveries with commercial value.

Professor Workman is an exceptionally experienced research leader, having achieved a high level of success in academia, biotech companies and the pharmaceutical industry. He is a Biochemist and Cancer Pharmacologist by training and he has worked at a number of academic institutions including Cambridge University, UK, Stanford University, California and the University of Glasgow, UK before moving to AstraZeneca, Alderley Park, UK as Head of the Cancer Bioscience Section in 1993.

In 1997, Paul joined The Institute of Cancer Research (ICR), London to build the Cancer Research UK Cancer Therapeutics Unit (CTU) and also co-founded two successful biotech companies, Piramed Pharma and Chroma Therapeutics. As well as being the Director of the ICR’s CTU and Harrap Professor of Pharmacology and Therapeutics, Paul was recently appointed Interim Chief Executive of ICR, having been Deputy CEO for the last 3 years.

Paul has received many scientific achievement awards including the American Association of Cancer Research Team Science Award (Team Leader) in 2012 and Cancer Research UK Translational Cancer Research Prize (Joint Leader of HSP90 Team) in 2013.

In addition, he has received both the Sosnovsky Award in Cancer Therapy (2010) and the World Entrepreneur of the Year Award (2012) from the Royal Society of Chemistry and earlier this year received the international Raymond Bourgine Award for excellence in cancer research.

“We are happy to further expand our collaboration with Paul and to have him join our expert advisory panel. Paul and his team at ICR have had a truly remarkable success rate and an outstanding track record in bringing compounds to the clinic” said Thomas Franch, CSO of Nuevolution. “We are certain that Paul’s expertise will help accelerate our oncology projects further to meet our ambitions of providing novel compounds for cancer treatment.”

Professor Workman said: “I am delighted to join Nuevolution’s advisors and am impressed by their proprietary Chemetics® technologies that provide an unprecedented capability for the identification of drug leads and a strong potential to address major unmet medical needs”.

Nuevolution is dedicated to the identification and progression of novel compounds addressing unmet medical needs with a main disease focus on Inflammation and Oncology.

The company currently has efforts on more than 30 disease targets at various discovery stages in its pipeline or in collaboration with several industrial, institutional and academic partners.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Brian Zambrowicz Joins Nuevolution as Director and Senior Scientific Advisor
Company also announces other Board of Directors.
Thursday, May 22, 2014
Nuevolution, Merck License Agreement
Agreement for small molecule compounds targeting an undisclosed intracellular target for use as leads in Merck’s drug discovery and development.
Friday, February 21, 2014
Nuevolution Announces Technology Licensing Agreement
Agreement with Novartis for use of Nuevolution’s Chemetics® technology.
Friday, January 10, 2014
Nuevolution Appoints Ton Berkien as Chief Business Officer
Ton Berkien will join the company on January 1, 2014.
Tuesday, December 10, 2013
Nuevolution Announces Formation of Strong Scientific Advisory Panel
Company teams with scientific advisors to assist the progression of its internal drug discovery programs.
Thursday, March 14, 2013
Nuevolution A/S Raises € 11 Million in New Financing Round
New financing round will enable Nuevolution to transform its current business model.
Friday, June 22, 2012
Nuevolution Announces Collaboration in Drug Discovery with Boehringer Ingelheim
Partnership to use Nuevolution's Chemetics® technology for lead discovery.
Wednesday, September 21, 2011
Nuevolution Enters Lead Discovery Collaboration in the Field of Epigenetic Disorders
A consortium has been established with the objective of identifying and developing novel small molecule drugs against epigenetic factors.
Thursday, October 07, 2010
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!